The Global Biopsy Device market was estimated to be worth $xx million in 2016. The market is anticipated to grow at a CAGR of 6.16% over the forecast period of 2018-2026. The Biopsy Device market is primarily driven by factors such as government pilot programs and initiatives, the rise in geriatric population, emerging number of diagnostic centres, recurrent revenue from repeat biopsy tests, etc.
The Global Biopsy Device market is classified into devices, therapeutic area, display technologies and end users which are further segmented as follows:
Devices are segmented into breast biopsy, robotic guidance system, gynaecological biopsy device, bronchial biopsy, GI biopsy, soft tissue biopsy needles etc. The therapeutic area is segmented into prostate biopsy, gynaecological biopsy, lung biopsy, kidney biopsy, liver biopsy, etc. The Display technologies are segmented into MRI guided biopsy, CT guided biopsy, stereotactic guided biopsy, and ultrasound-guided biopsy. The End Users are segmented into diagnosis centres and hospitals.
Geographically, the global Biopsy Device market is divided into North America, Europe, Asia-Pacific and the rest of the world. The North American market is expected to hold the biggest share by the end of the forecast period with Mexico being the most popular country in the region in terms of offering non-traditional holistic treatments for people diagnosed with cancer. On the other hand, the Asia-Pacific market is predicted to be the fastest-growing region for the Biopsy Device market over the forecast period with countries like India and China being its major contributors.
Some of the major market companies in the Global Biopsy Device market are AD-Tech Medical Instrument Corp, B. Braun Melsungen Ag, C. R. Bard, Inc., Fischer Medical Technologies LLC, and Planmeca Oy, amongst others.